All Hands on Deck: Youth, Therapists, Parents and School Professionals Joining Forces in a Personalized, Brief and Intensive Exposure-based Intervention for Youth With Persistent Anxiety or Obsessive Compulsive Disorder

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Methods: A multiple baseline single-case experimental design is used (qualitative and quantitative). Participants are children/adolescents (10-18 years; N=12) with an AD/OCD diagnosis for whom standard CBT did not lead to sufficient improvement. Children and parents are asked to complete questionnaires before, during, and after the treatment. Children, parents, and school professionals will be asked to participate in qualitative interviews to evaluate their experiences with the HANDS-ON treatment program.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 18
Healthy Volunteers: f
View:

• Age between 10-18 years old;

• Meeting DSM-5 criteria for an anxiety disorder/OCD, based on a semi-structured interview (SCID-5 Jr; \[12\]) and clinical judgement of an experienced and authorized clinician;

• Non-responder to previous CBT (insufficient benefits from previous CBT for AD/OCD).

⁃ Comorbid diagnoses are allowed except for those interfering with safety or warranting immediate treatment, e.g., acute suicidality or psychosis.

Locations
Other Locations
Netherlands
Accare
RECRUITING
Groningen
Contact Information
Primary
L. Wolters, Dr.
l.wolters@accare.nl
(050) 368 11 00
Backup
C. O. W. Ganzevoort, MSc
c.ganzevoort@accare.nl
Time Frame
Start Date: 2023-12-04
Estimated Completion Date: 2025-12
Participants
Target number of participants: 12
Treatments
Experimental: HANDS-ON treatment with random baselines
Participants are randomly allocated to one of four baseline periods (2.5 weeks, 3 weeks, 3.5 weeks, or 4 weeks). Participants then receive the HANDS-ON treatment. This treatment consists of three phases across nine weeks. After the treatment, there is a follow-up period of 4 weeks.
Related Therapeutic Areas
Sponsors
Leads: Accare

This content was sourced from clinicaltrials.gov